The Pathologic Diagnosis and Clinical Therapy of Neuroendocrine Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 1339
Special Issue Editors
Interests: neuroendocrine tumors; rare tumors; pathology; molecular oncology; cancer biomarkers
Special Issues, Collections and Topics in MDPI journals
Interests: cancer biology; molecular oncology; cancer metastasis; clinical trials; cancer biomarkers
Interests: clinical oncology; rare tumors; neuroendocrine tumors; medical oncology; cancer metastasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The selection of optimal therapy for patients with NEN is challenging due to tumor physiological heterogeneity and variable aggressiveness. The involvement of widely distributed neuroendocrine cells helps to diagnose NEN based on regional clinical features and hormone-related specific clinical features of secretion, but most tumors remain undiagnosed until a later stage. Their potential to metastasize, their diverse histopathology, their presentation as part of genetic syndromes, and their symptomatic treatments contribute to confusion in early diagnosis. Elucidating the molecular complexities and clinical nuances, especially in advanced stages, is of paramount importance in shaping the future of clinical research in NENs to advance targeted therapeutic strategies and improve patient stratification.
Different types of articles are welcome in this Special Issue, including reviews and original research. Specifically, we encourage clinical investigations that address more nuanced prognostic factors, in-depth analyses of molecular signatures that delineate clinical outcomes, the exploration of cutting-edge therapeutic interventions guided by a nuanced understanding of late-stage prognostic considerations, and pharmacological and translational research that bridges the patient-to-patient test–bed gap by translating molecular discoveries into clinically usable prognostic tools. It is important to note that studies that report only on the analysis of publicly available datasets will not be taken into consideration for this Special Issue. You are invited to help us drive a paradigm shift in NET cancer care through the publication of rigorous scientific research.
Dr. Annabella Di Mauro
Dr. Ottavia Clemente
Dr. Salvatore Tafuto
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine neoplasms
- molecular mechanisms
- cancer pathogenesis
- tumorigenesis
- diagnosis
- molecular and cellular heterogeneity
- predictive biomarkers
- animal models and of neuroendocrine cancer
- diagnostic clinical oncology
- genomic characterization
- clinical biomarkers
- biomarkers of drug response
- epigenetic biomarkers
- targeted therapy
- tumor immunity
- molecular oncology
- clinical therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
